Level 1: In situ melanoma Level 2: Melanoma has invaded the papillary dermis Level 3: Melanoma has filled the papillary dermis Level 4: Melanoma has invaded the reticular dermis Level 5: Melanoma has invaded the subcutaneous tissue Margins of excisionthe normal tissue around a tumour Mitotic ratea measure of how fast the cells are proliferating Presence of ulceration
Chen et al., 2023)
Patients can report suspected side effects to medicines via the Yellow Card scheme at yellowcard
This dual-action mechanism explains why it is highly sought after as a solution for metabolic health challenges
Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Supplements include probiotics, melatonin, and flaxseed
